Purpose: To determine the short-and long-term efficacy and toxicity of the high-dose
intravenous bolus interleukin 2 (IL-2) regimen in patients with metastatic melanoma. Patients …

The immune suppressive molecule programmed death-1 (PD-1) is upregulated in activated
T lymphocytes and inhibits T-cell function upon binding to its ligands B7-H1 (PD-L1, CD274) …

Insulin-dependent diabetes may occur in patients with cancers who are treated with
checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two …

Background Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T
cells, can overcome immune resistance. We assessed the antitumor activity and safety of …

Background Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab
(a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been …

Background In patients with melanoma, ipilimumab (an antibody against cytotoxic T-
lymphocyte–associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an …

Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can
result in durable responses in patients with melanoma who have progressed after …

Purpose Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T
cells that downmodulates effector functions and limits the generation of immune memory. PD …

PURPOSE To determine the efficacy and toxicity of a high-dose interleukin-2 (IL-2) regimen
in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS Two hundred …

We characterized the mutational landscape of melanoma, the form of skin cancer with the
highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed …